Format

Send to

Choose Destination
See comment in PubMed Commons below
AIDS Behav. 2009 Feb;13(1):1-9. doi: 10.1007/s10461-008-9401-5. Epub 2008 May 16.

Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions.

Author information

1
Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, CA, 94143, USA. moupali.das-douglas@ucsf.edu.

Abstract

Antiretroviral (ARV) treatment interruptions are associated with virologic rebound, drug resistance, and increased morbidity and mortality. The Medicare Part D prescription drug benefit, implemented on January 1st, 2006, increased consumer cost-sharing. Consumer cost-sharing is associated with decreased access to medications and adverse clinical outcomes. We assessed the association of Part D implementation with treatment interruptions by studying 125 HIV-infected homeless and marginally housed individuals with drug coverage receiving ARV therapy. Thirty-five percent of respondents reported Medicare coverage and 11% reported ARV interruptions. The odds of ARV interruptions were six times higher among those with Part D coverage and remained significant after adjustment. The majority of Part D-covered respondents reporting ARV interruptions cited increased cost as their primary barrier. Directed interventions to monitor the long-term effects of increased cost burden on interruptions and clinical outcomes and to reduce cost burden are necessary to avoid preventable increases in morbidity and mortality.

PMID:
18483850
PMCID:
PMC3591735
DOI:
10.1007/s10461-008-9401-5
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center